Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML published in the Journal of Hematology & Oncology November 24, 2025
Kura Oncology Receives $30M Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin October 29, 2025
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline October 29, 2025
FDA Approves Revuforj® (revumenib) in Adult & Pediatric Patients with R/R NPM1 Mutated AML October 29, 2025
Initial clinical data on the combination of AB8939 + venetoclax in the first three patients with R/R AML announced October 15, 2025
Pivotal Ziftomenib Data in R/R NPM1-Mutated AML Published in the Journal of Clinical Oncology September 30, 2025
Revuforj® (revumenib) Included in NCCN Guidelines for the Treatment of R/R NPM1 Mutated AML September 23, 2025
CHARM Therapeutics raises $80M in Series B financing to advance development of menin inhibitor for AML September 3, 2025
Early Data Demonstrates Tuspetinib Improves SOC Treatment Across Diverse Populations of Newly Diagnosed AML in Ph 1/2 TUSCANY Trial August 19, 2025
Patient deaths trigger discontinuation of Ph 1 trial from SGR-2921 Program in R/R AML and HR-MDS patients August 19, 2025
Enrollment Open for 160 mg Dosing Cohort of Tuspetinib in Ph 1/2 TUSCANY Trial of 1L Triple Drug Therapy in induction-ineligible AML patients August 12, 2025
